1437310-67-2

Upstream product

• 179688-53-0 6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 
• 905306-05-0 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-ol 
• 109-70-6 1.3-chlorobromopropane 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 179688-52-9 6-hydroxy-7-methoxyquinazolin-4(3H)-one 
• 905306-07-2 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-yl acetate 
• 1315512-62-9 5-(3-chloropropoxy)-4-methoxy-2-aminobenzonitrile 
• 1315512-61-8 C₁₁H₁₁ClN₂O₄ 
• 54060-30-9 3-acetylenephenylamine 

Downstream Products

• 1438085-67-6 tert-butyl 5-(3-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438074-57-7 N-(3-ethynylphenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438074-63-5 6-(3-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)propoxy)-N-(3-ethynylphenyl)-7-methoxyquinazolin-4-amine 
• 1438072-23-1 N-(3-ethynylphenyl)-7-methoxy-6-(3-(tetrahydro-2H-[1,4]dioxino[2,3-c]pyrrol-6(3H)-yl)propoxy)quinazolin-4-amine 

Relevant academic research and scientific papers

Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase

A series of novel quinazoline-1-deoxynojirimycin hybrids were designed, synthesized and evaluated for their inhibitory activities against two drug target enzymes, epidermal growth factor receptor (EGFR) tyrosine kinase and α-glucosidase. Some synthesized compounds exhibited significantly inhibitory activities against the tested enzymes. Comparing with reference compounds gefitinib and lapatinib, compounds 7d, 8d, 9b and 9d showed higher inhibitory activities against EGFR (IC50: 1.79–10.71 nM). Meanwhile the inhibitory activities of 7d, 8d and 9c against α-glucosidase (IC50 = 0.14, 0.09 and 0.25 μM, respectively) were obvious higher than that of miglitol (IC50 = 2.43 μM), a clinical using α-glucosidase inhibitor. Interestingly, compound 9d as a dual inhibitor showed high inhibitory activity to EGFRwt tyrosine kinase (IC50 = 1.79 nM), also to α-glucosidase (IC50 = 0.39 μM). The work could be very useful starting point for developing a new series of enzyme inhibitors targeting EGFR and/or α-glucosidase.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.